AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12404705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (GK501)
Number of subjects: 0
Study 12404705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (G115)
Number of subjects: 0
Study 12404705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo-Ginseng combination (320 mg)
Number of subjects: 0
Study 12404705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo-Ginseng combination (640 mg)
Number of subjects: 0
Study 12404705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo-Ginseng combination (960 mg)
Number of subjects: 0
Study 12404705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10102436 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/d for 1 week)
Number of subjects: 20
Study 10102436 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (100 mg/kg in three divided doses at 2‐hour intervals)
Number of subjects: 20
Study 10102436 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 20
Study 10102436 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 20
Study 7598284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus followed by 20-min infusion at 9 micrograms.kg-1.min-1)
Number of subjects: 12
Study 7598284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone (20 mg daily for 14 days)
Number of subjects: 30
Study 2219614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone
Number of subjects: 30
Study 282702 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline as a vasoconstrictor
Number of subjects: 51
Study 282702 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline as a vasoconstrictor
Number of subjects: 51
Study 31618495 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 404
Study 31618495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 30533601 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH-IT (Competent Adulthood Transition with Cognitive Behavioral Humanistic and Interpersonal Training)
Number of subjects: 369
Study 30533601 — intervention group
Group type: COMPARATOR
Intervention: General Health Education (HE)
Number of subjects: 369
Study 26826543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 135
Study 26826543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 24894850 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy (ART) commenced at ≤4 months post radical prostatectomy
Number of subjects: 470
Study 24894850 — intervention group
Group type: COMPARATOR
Intervention: Observation with early salvage radiotherapy (SRT) triggered by PSA level >0.20 ng/mL
Number of subjects: 470
Study 24894850 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy (ART)
Number of subjects: 470
Study 24894850 — intervention group
Group type: COMPARATOR
Intervention: Observation with early salvage radiotherapy (SRT)
Number of subjects: 470
Study 21630047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 282
Study 21630047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 282
Study 21630047 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 282
Study 20645280 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction data from four treatment arms
Number of subjects: 0
Study 20645280 — intervention group
Group type: COMPARATOR
Intervention: Beta likelihood ratio test
Number of subjects: 0
Study 17049197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferulate, determined using HPLC-ESI-MS method
Number of subjects: 20
Study 16260426 — intervention group
Group type: EXPERIMENTAL
Intervention: Monascus purpureus Went rice (600 mg)
Number of subjects: 79
Study 16260426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 14624833 — intervention group
Group type: COMPARATOR
Intervention: Task-specific self-instruction intervention for handwriting (3 months, individual basis)
Number of subjects: 7
Study 14624833 — intervention group
Group type: COMPARATOR
Intervention: Task-specific self-instruction intervention for handwriting (6 months, group setting)
Number of subjects: 7
Study 14624833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7
Study 11185676 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1200 mg oral dose
Number of subjects: 12
Study 11185676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 750 mg q8h for 11 days with concurrent azithromycin 1200 mg on Day 9
Number of subjects: 12
Study 11185676 — intervention group
Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 12
Study 8685657 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 803
Study 8685657 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 803
Study 1825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol, 100 micrograms/dose
Number of subjects: 120
Study 1825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol, 200 micrograms/dose
Number of subjects: 120
Study 1825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol, 50 micrograms and ipratropium, 20 micrograms/dose in a single inhaler (Berodual)
Number of subjects: 120
Study 1825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol, 100 micrograms and ipratropium, 40 micrograms/dose in a single inhaler (Duovent)
Number of subjects: 120
Study 1825266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose combination
Number of subjects: 120
Study 1825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fenoterol and low-dose combination
Number of subjects: 120
Study 6341842 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 40
Study 6341842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Dextrose)
Number of subjects: 40
Study 29552984 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban plus aspirin
Number of subjects: 203
Study 29552984 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 203
Study 27846071 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ARV adherence (81%-98%)
Number of subjects: 263
Study 27846071 — intervention group
Group type: EXPERIMENTAL
Intervention: Near perfect ARV adherence (>98%)
Number of subjects: 263
Study 27846071 — intervention group
Group type: COMPARATOR
Intervention: Detectable breastmilk RNA (≥40 copies/mL)
Number of subjects: 263
Study 25230136 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterjet-assisted ESD
Number of subjects: 117
Study 25230136 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD
Number of subjects: 117
Study 22782052 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil extract
Number of subjects: 60
Study 22782052 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 60
Study 22782052 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B
Number of subjects: 60
Study 22782052 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) and 2% chlorhexidine gel (CHX)
Number of subjects: 60
Study 22782052 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 60
Study 19475583 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (specific medications not detailed)
Number of subjects: 710
Study 19475583 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate gene analysis (128 candidate genes studied)
Number of subjects: 710
Study 18054633 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling surgery (SB)
Number of subjects: 681
Study 18054633 — intervention group
Group type: COMPARATOR
Intervention: Primary vitrectomy (PPV)
Number of subjects: 681
Study 15843336 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions that modulate suicide ideation (specific interventions not detailed in the abstract)
Number of subjects: 19
Study 15843336 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study 12163424 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus moderate-intensity coumarin (3-month regimen)
Number of subjects: 308
Study 12163424 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 308
Study 9564799 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/day fluticasone propionate (FP)
Number of subjects: 16
Study 9564799 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 microg/day triamcinolone acetonide (TAA)
Number of subjects: 16
Study 9564799 — intervention group
Group type: EXPERIMENTAL
Intervention: 336 microg/day beclomethasone dipropionate (BDP)
Number of subjects: 16
Study 9564799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9050533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide pneumoperitoneum
Number of subjects: 105
Study 9050533 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 105
Study 3046350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (5 mg/kg every eight hours) for five days
Number of subjects: 82
Study 3046350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 30069912 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 13
Study 30082261 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMA Supreme stent
Number of subjects: 72
Study 30082261 — intervention group
Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 72
Study 27012401 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-stress cardiac magnetic resonance (CMR) imaging
Number of subjects: 117
Study 24682356 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self-correction and task-oriented exercises
Number of subjects: 110
Study 24682356 — intervention group
Group type: COMPARATOR
Intervention: Traditional spinal exercises
Number of subjects: 110
Study 21450569 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 4 weeks
Number of subjects: 39
Study 21450569 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 39
Study 21450569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 39
Study 20082696 — intervention group
Group type: EXPERIMENTAL
Intervention: Class-based exercise (FAME)
Number of subjects: 0
Study 20082696 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (OEP)
Number of subjects: 0
Study 20082696 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17327249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal continence pessary
Number of subjects: 0
Study 17327249 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (including pelvic floor muscle training and exercise and bladder control strategies)
Number of subjects: 0
Study 17327249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravaginal continence pessary and behavioral therapy
Number of subjects: 0
Study 16291891 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)‐tetrahydrocannabinol (Delta(9)‐THC)
Number of subjects: 630
Study 16291891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis extract
Number of subjects: 630
Study 16291891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 11943517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine 5-mg/24-hour patch
Number of subjects: 36
Study 11943517 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 36
Study 9718784 — intervention group
Group type: EXPERIMENTAL
Intervention: Double aspirative drain
Number of subjects: 0
Study 9718784 — intervention group
Group type: COMPARATOR
Intervention: Double open Silastic drain
Number of subjects: 0
Study 7795367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single transvaginal ultrasonographic evaluation with plasma hCG determination
Number of subjects: 260
Study 7795367 — intervention group
Group type: COMPARATOR
Intervention: Viable pregnancy group
Number of subjects: 260
Study 2646301 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCS + i.m. HRIG 20 IU/kg
Number of subjects: 30
Study 2646301 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. HRIG alone 15 IU/kg
Number of subjects: 30
Study 2646301 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCS + i.v. HRIG 15 IU/kg
Number of subjects: 30
Study 2646301 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCS + HRIG 5 IU/kg i.v. plus 10 IU/kg i.m.
Number of subjects: 30
Study 2646301 — intervention group
Group type: COMPARATOR
Intervention: HDCS alone
Number of subjects: 30
Study 1100299 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana (25 mug/kg THC)
Number of subjects: 12
Study 1100299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium secobarbital (150 mg/70 kg)
Number of subjects: 12
Study 1100299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of marihuana and secobarbital
Number of subjects: 12
Study 1100299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6102180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (3 doses of 1 g each)
Number of subjects: 515
Study 31192710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene education for 10 minutes via video, applied for 3 days
Number of subjects: 46
Study 31192710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 31192710 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education vs Control
Number of subjects: 46
Study 28645737 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfapump® (AP)
Number of subjects: 60
Study 26372927 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and NG infection
Number of subjects: 1373
Study 26372927 — intervention group
Group type: EXPERIMENTAL
Intervention: CT infection
Number of subjects: 1373
Study 23422464 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxing training
Number of subjects: 31
Study 23422464 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise
Number of subjects: 31
Study 23422464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 21175792 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with probiotic-containing yogurt (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium longum, and Streptococcus thermophilus)
Number of subjects: 337
Study 21175792 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy without yogurt (control group)
Number of subjects: 337
Study 21175792 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with probiotic-containing yogurt
Number of subjects: 337
Study 19752879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5HTP-Nat Exts
Number of subjects: 27
Study 19752879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17361128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose, 15 mg maintenance dose) with ketoconazole (400 mg/day)
Number of subjects: 0
Study 17361128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) with ketoconazole (400 mg/day)
Number of subjects: 0
Study 17361128 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) without ketoconazole
Number of subjects: 0
Study 17361128 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel (60 mg loading dose, 15 mg maintenance dose) without ketoconazole
Number of subjects: 0
Study 15375502 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT group (1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen)
Number of subjects: 136
Study 15375502 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT group
Number of subjects: 136
Study 15375502 — intervention group
Group type: COMPARATOR
Intervention: CMFT group (CMF + tamoxifen)
Number of subjects: 136
Study 11453171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 7
Study 10204352 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosorption (IS) with DNA-containing active carbon
Number of subjects: 22
Study 10204352 — intervention group
Group type: COMPARATOR
Intervention: Nonselective hemosorption (NHS) with carbon
Number of subjects: 22
Study 10204352 — intervention group
Group type: COMPARATOR
Intervention: Control carbon (NHS)
Number of subjects: 22
Study 10204352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IS and NHS
Number of subjects: 22
Study 8144266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.85 g/kg dose of alcohol
Number of subjects: 0
Study 8144266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2974411 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 percent propylene glycol, 50 percent ethanol, and 35 percent water
Number of subjects: 39
Study 2974411 — intervention group
Group type: COMPARATOR
Intervention: 50 percent ethanol and 50 percent water
Number of subjects: 39
Study 30772070 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR (PXVX0200) 1 × 10^9 CFU
Number of subjects: 2979
Study 30772070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2979
Study 30772070 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR (PXVX0200)
Number of subjects: 2979
Study 28787737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet I (low in carbohydrates)
Number of subjects: 283
Study 28787737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet II (low in fat)
Number of subjects: 283
Study 26418666 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + L (scaling and root planing plus adjunctive laser therapy)
Number of subjects: 22
Study 26418666 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing alone)
Number of subjects: 22
Study 26418666 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + L
Number of subjects: 22
Study 26418666 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 22
Study 23223117 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IV ketamine (group K)
Number of subjects: 190
Study 21669126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon β‐1a (IM IFN‐β‐1a)
Number of subjects: 286
Study 19136898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid discontinuation of prednisone (RDP)
Number of subjects: 0
Study 19136898 — intervention group
Group type: COMPARATOR
Intervention: Historical controls with maintenance prednisone
Number of subjects: 0
Study 19136898 — intervention group
Group type: EXPERIMENTAL
Intervention: RDP
Number of subjects: 0
Study 19136898 — intervention group
Group type: COMPARATOR
Intervention: Maintenance prednisone
Number of subjects: 0
Study 16962524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg granisetron (Group A, n=70)
Number of subjects: 140
Study 16962524 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Group B, n=70)
Number of subjects: 140
Study 27932764 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 18
Study 27932764 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% intralipid
Number of subjects: 18
Study 27932764 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 18
Study 10352054 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support according to a breastfeeding protocol for twins
Number of subjects: 18
Study 10352054 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 18
Study 10352054 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Number of subjects: 18
Study 8766398 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with piritramide (bolus 2.5 mg, blocking time 20 minutes, no basal infusion)
Number of subjects: 74
Study 8766398 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with bupivacaine 0.5% and intravenous PCA (same parameters as group 1) plus continuous epidural infusion of bupivacaine 0.1875% at 8 ml/h
Number of subjects: 74
Study 1928855 — intervention group
Group type: COMPARATOR
Intervention: No haemodilution (Control group)
Number of subjects: 16
Study 1928855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute isovolaemic haemodilution (AIH)
Number of subjects: 16
Study 1928855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 7201271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, 8 micrograms/kg with thiopental, 3 mg/kg
Number of subjects: 36
Study 7201271 — intervention group
Group type: COMPARATOR
Intervention: Thiopental, 6 mg/kg alone
Number of subjects: 36
Study 31918574 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotape plus exercise
Number of subjects: 60
Study 31918574 — intervention group
Group type: COMPARATOR
Intervention: Sham kinesiotape plus exercise
Number of subjects: 60
Study 31344787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined ergonomics and neck/shoulder strengthening exercise intervention (EET)
Number of subjects: 177
Study 31344787 — intervention group
Group type: COMPARATOR
Intervention: 12-week combined ergonomics and health promotion intervention (EHP)
Number of subjects: 177
Study 29663701 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL 0.1% cream
Number of subjects: 40
Study 29663701 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL 0.05% cream
Number of subjects: 40
Study 26850746 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (∼1.8 g/day) for ∼14 days
Number of subjects: 61
Study 26850746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 25208366 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste (0.3% triclosan, 2% copolymer, 0.243% sodium fluoride)
Number of subjects: 75
Study 25208366 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75